# Calluna Pharma AS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calluna-pharma

- Industry: Biotechnology
- Headquarters: Oslo, Norway
- Website: www.callunapharma.com/
- Total disclosed funding: $82M
- Latest round: Series A (Jan 23, 2024)
- Investors on record: 4

## About

Based in Oslo, Norway, and founded in 2024, Calluna Pharma AS, formed from the merger of Oxitope Pharma and Arxx Therapeutics, operates as a clinical-stage biotechnology company. In January 2024, the firm raised EUR 75 million in series A funding led by investor Forbion, with participation from other investors Sarsia Management, P53, and Investinor. The firm as of January 2024, is led by its Chairman, Marco Boorsma, and CEO, John Montana.

The company offers therapeutic solutions to improve patient outcomes in diseases like inflammatory and fibrotic diseases, where existing treatments are sub-optimal. Calluna adopts a therapeutic approach and precision targets upstream innate immune amplifiers developing a pipeline of therapeutic antibodies to restore tissue homeostasis and disrupt disease progression. Spearheading their portfolio is CAL101, a monoclonal antibody designed to neutralize S100A4, offering hope to patients with conditions like idiopathic pulmonary fibrosis, chronic kidney disease, and severe asthma. Other 3 therapies in the pipeline of the firm include CAL102, CAL103, and CAL104 for MI reperfusion injury, chronic pipeline, and chronic indication respectively.

The company plans to utilize the January 2024 funding to develop novel therapies for inflammatory and fibrotic diseases.

## Funding rounds

- Series A, Jan 23, 2024, $82M — Forbion, Sarsia, Investinor, p53

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Sarsia (https://capitalatlas.ai/funds/sarsia) — Series A
- Investinor (https://capitalatlas.ai/funds/investinor) — Series A
- p53 (https://capitalatlas.ai/funds/p53) — Series A